Price (delayed)
$16.855
Market cap
$22.25M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$18.71
Enterprise value
$2.52M
Pieris Pharmaceuticals Inc.is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Its pipeline includes inhalable Anticalin
There are no recent dividends present for PIRS.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.